Advertisement

Individualized Protease Inhibitor Monotherapy: The Role of Pharmacokinetics and Pharmacogenetics in an Aged and Heavily Treated HIV-Infected Patient

  • Elena López Aspiroz
  • Salvador Enrique Cabrera FigueroaEmail author
  • María Paz Valverde Merino
  • Ángel Carracedo Álvarez
Case Report

Abstract

Antiretroviral therapy has changed the history of HIV infection from a lethal disease to a chronic infection, with the emergence of long-term adverse effects. Herein we present a case of a heavily treated HIV-infected man in whom antiretroviral toxicity had been observed. The lopinavir/ritonavir plasma concentrations at standard doses were significantly above the recommended levels. Pharmacogenetic analysis revealed a polymorphism in the DRD3 gene associated with a decrease in the rate of drug metabolism. Additionally, the patient’s low body mass index could have contributed to a greater degree of patient exposure to the drug. After the withdrawal of tenofovir disoproxil and the establishment of individualized protease inhibitor monotherapy at reduced doses, a decrease in the intensity of adverse events was observed, while the clinical outcomes were maintained. The pharmacokinetic-pharmacogenetic analysis was shown to be a tool of huge interest for the management and durability of antiretroviral therapy.

Notes

Acknowledgements

Pure lopinavir and ritonavir compounds were kindly provided by Abbott Laboratories. These substances were used both as standards for the analytical technique validation and as standards in all quantitative determinations.

Compliance with Ethical Standards

Funding

No source of funding.

Conflict of interest

Elena López Aspiroz, Salvador Enrique Cabrera Figueroa, María Paz Valverde Merino and Ángel Carracedo declare that they have no conflicts of interest.

Ethics approval

All procedures in this study were in accordance with the 1964 Helsinki Declaration; the Ethics Committee of the University Hospital of Salamanca (Spain) approved the study.

Informed consent

Written informed consent was obtained from the patient.

References

  1. 1.
    Sabin CA. Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy? BMC Med. 2013;11:251.CrossRefGoogle Scholar
  2. 2.
    Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS. 2013;27:973–9.CrossRefGoogle Scholar
  3. 3.
    Carr A, Miller J, Law M, et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14:F25–32.CrossRefGoogle Scholar
  4. 4.
    Maagaard A, Kvale D. Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms? J Antimicrob Chemother. 2009;64:901–9.CrossRefGoogle Scholar
  5. 5.
    Chawla A, Wang C, Patton C, et al. A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population. Infect Dis Ther. 2018.  https://doi.org/10.1007/s40121-018-0201-6.Google Scholar
  6. 6.
    Garrabou G, Morén C, Gallego-Escudero JM, et al. Genetic and functional mitochondrial assessment of HIV-infected patients developing HAART-related hyperlactatemia. J Acquir Immune Defic Syndr. 2009;52:443–51.CrossRefGoogle Scholar
  7. 7.
    European AIDS Clinical Society. Guidelines. Clinical management and treatment of HIV-infected adults in Europe. Version 9.1. 2018.Google Scholar
  8. 8.
    Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/guidelines. Accessed Jan 11 2018.
  9. 9.
    Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2018).Google Scholar
  10. 10.
    Colasanti J, Marconi VC, Taiwo B. Antiretroviral reduction: is it time to rethink the unthinkable? AIDS. 2014;28:943–7.CrossRefGoogle Scholar
  11. 11.
    Pulido F, Pérez-Valero I, Delgado R, et al. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther. 2009;14:195–201.Google Scholar
  12. 12.
    Arribas JR, Delgado R, Arranz A, et al. Lopinavir–ritonavir monotherapy versus lopinavir–ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr. 2009;51:147–52.CrossRefGoogle Scholar
  13. 13.
    Arribas JR, Clumeck N, Nelson M, et al. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load. HIV Med. 2012;13:398–405.CrossRefGoogle Scholar
  14. 14.
    Cabrera Figueroa S, Iglesias Gómez A, Sánchez Martín A, et al. Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV. Clin Drug Investig. 2010;30:405–11.CrossRefGoogle Scholar
  15. 15.
    Schoenenberger JA, Aragones AM, Cano SM, et al. The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems. Ther Drug Monit. 2013;35:71–7.CrossRefGoogle Scholar
  16. 16.
    López Aspiroz E, Cabrera Figueroa SE, Porras Hurtado GL, et al. Pharmacogenetic analysis of SNPs in genes involved in the pharmacokinetics and response to lopinavir/ritonavir therapy. Curr Drug Metab. 2013;14:729–37.CrossRefGoogle Scholar
  17. 17.
    López Aspiroz E, Santos Buelga D, Cabrera Figueroa SE, et al. Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients. Per Med. 2014;11:693–704.CrossRefGoogle Scholar
  18. 18.
    López Aspiroz E, Cabrera Figueroa SE, Iglesias Gómez A, et al. CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman. Clin Drug Investig. 2015;35:61–6.CrossRefGoogle Scholar
  19. 19.
    Sánchez A, Cabrera S, Santos D, et al. Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients. Antimicrob Agents Chemother. 2011;55:5314–24.CrossRefGoogle Scholar
  20. 20.
    Masquelier B, Breilh D, Neau D, et al. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir–ritonavir containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2002;46:2926–32.CrossRefGoogle Scholar
  21. 21.
    Gutiérrez F, Padilla S, Navarro A, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir containing regimens. J Acquir Immune Defic Syndr. 2003;33:594–600.CrossRefGoogle Scholar
  22. 22.
    Van der Leur MR, Burger DM, la Porte CJ, et al. A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIVinfected adults. Ther Drug Monit. 2006;28:650–3.CrossRefGoogle Scholar
  23. 23.
    Moltó J, Blanco A, Miranda C, et al. Variability in nonnucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice. Br J Clin Pharmacol. 2006;62:560–6.CrossRefGoogle Scholar
  24. 24.
    Arab-Alameddine M, Lubomirov R, Fayet-Mello A, et al. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. J Antimicrob Chemother. 2014;69:2489–98.CrossRefGoogle Scholar
  25. 25.
    Ma Q, Brazeau D, Zingman BS, et al. Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics. 2007;8:227–35.CrossRefGoogle Scholar
  26. 26.
    Elens L, Yombi JC, Lison D, et al. Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. Pharmacogenomics. 2009;10:1589–97.CrossRefGoogle Scholar
  27. 27.
    Hartkoorn RC, Kwan WS, Shallcross V, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genom. 2010;20:112–20.CrossRefGoogle Scholar
  28. 28.
    Lubomirov R, Iulio J, Fayet A, et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genom. 2010;20:217–30.Google Scholar
  29. 29.
    Boffito M, Miralles D, Hill A. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients. HIV Clin Trials. 2008;9:418–27 (Review. Erratum in: HIV Clin Trials. 2009;10:vi).CrossRefGoogle Scholar
  30. 30.
    Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120–6.CrossRefGoogle Scholar
  31. 31.
    Lim Y, Lyall H, Foster C. Tenofovir-associated nephrotoxicity in children with perinatally-acquired HIV infection: a single-centre cohort study. Clin Drug Investig. 2015;35:327–33.CrossRefGoogle Scholar
  32. 32.
    Yombi JC, Pozniak A, Boffito M, et al. Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. AIDS. 2014;28:621–32.CrossRefGoogle Scholar
  33. 33.
    Ryom L, Mocroft A, Kirk O, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D Study. J Infect Dis. 2013;207:1359–69.CrossRefGoogle Scholar
  34. 34.
    Casado JL. Renal and bone toxicity with the use of tenofovir: understanding at the end. AIDS Rev. 2016;18:59–68.Google Scholar
  35. 35.
    Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008;83:265–72.CrossRefGoogle Scholar
  36. 36.
    Giacomet V, Nannini P, Vigano A, et al. Long-term renal effects of tenofovir–disoproxil–fumarate in vertically HIV-infected children, adolescents, and young adults: a 132-month follow-up study. Clin Drug Investig. 2015;35:419–26.CrossRefGoogle Scholar
  37. 37.
    Casado JL, Del Rey JM, Bañón S, et al. Changes in kidney function and in the rate of tubular dysfunction after tenofovir withdrawal or continuation in HIV-infected patients. J Acquir Immune Defic Syndr. 2016;72:416–22.CrossRefGoogle Scholar
  38. 38.
    Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20:2165–74.CrossRefGoogle Scholar
  39. 39.
    Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009;51:554–61.CrossRefGoogle Scholar
  40. 40.
    Castronuovo D, Cacopardo B, Pinzone MR, et al. Bone disease in the setting of HIV infection: update and review of the literature. Eur Rev Med Pharmacol Sci. 2013;17:2413–9.Google Scholar
  41. 41.
    Carrero A, Ryan P. Tenofovir y enfermedad ósea en pacientes infectados por el VIH. REEMO (Revista Española de Enfermedades Metabólicas Oseas). 2009;18:56–62.CrossRefGoogle Scholar
  42. 42.
    Borges AH, Hoy J, Florence E, et al. Antiretrovirals, fractures, and osteonecrosis in a large international HIV cohort. Clin Infect Dis. 2017;64:1413–21.CrossRefGoogle Scholar
  43. 43.
    López Aspiroz E, Cabrera Figueroa SE, Domínguez-Gil Hurlé A, et al. New strategies in the optimisation of lopinavir/ritonavir doses in human immunodeficiency virus-infected patients. Enferm Infecc Microbiol Clin. 2013;31:36–43 (Review. Spanish.).CrossRefGoogle Scholar
  44. 44.
    Hervé D. Identification of a specific assembly of the g protein golf as a critical and regulated module of dopamine and adenosine-activated cAMP pathways in the striatum. Front Neuroanat. 2011;5:1–9.CrossRefGoogle Scholar
  45. 45.
    Peschl L. Clinical and experimental investigations of the effect of dopamine on haemodynamics and function of kidney and liver (author’s transl). Wien Klin Wochenschr. 1978;86:1–33.Google Scholar
  46. 46.
    Hongju Yang AE, Lianmei Zhong AB, Song Bai AC, et al. Association of dopamine D1 and D3 receptor gene polymorphisms with essential hypertension in 3 ethnic groups in China. Med Sci Monit Basic Res. 2017;23:234–9.CrossRefGoogle Scholar
  47. 47.
    Del Zompo M, Cherchi A, Palmas MA, et al. Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology. 1998;51:781–6.CrossRefGoogle Scholar
  48. 48.
    León-Cachón RBR, Ascacio-Martínez JA, Gamino-Peña ME, et al. A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers. BMC Cancer. 2016;16:74.CrossRefGoogle Scholar
  49. 49.
    Daskapan A, Stienstra Y, Kosterink JGW, et al. Risk factors contributing to a low darunavir plasma concentration. Br J Clin Pharmacol. 2018;84:456–61.CrossRefGoogle Scholar
  50. 50.
    Lê MP, Chaix ML, Chevret S, et al. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study. J Antimicrob Chemother. 2018;73:2120–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Elena López Aspiroz
    • 1
  • Salvador Enrique Cabrera Figueroa
    • 2
    • 3
    Email author
  • María Paz Valverde Merino
    • 4
  • Ángel Carracedo Álvarez
    • 5
    • 6
  1. 1.Pharmacy ServiceUniversity Hospital Infanta SofíaMadridSpain
  2. 2.Pharmacy Department, Pharmacy FacultyUniversity of ConcepcionConcepciónChile
  3. 3.Pharmacy ServiceRegional Clinical Dr. Guillermo Grant Benavente HospitalConcepciónChile
  4. 4.Pharmacy ServiceUniversity Hospital of SalamancaSalamancaSpain
  5. 5.Galician Public Foundation of Genomic Medicine, Health Research Institute of Santiago (IDIS)Santiago de CompostelaSpain
  6. 6.Genomic Medicine Group, CIBERER, CIMUS (Centre for Research in Molecular Medicine and Chronic Diseases)University of Santiago de CompostelaSantiago de CompostelaSpain

Personalised recommendations